APYX Stock Forecast & Price Target

Apyx Medical is expected to experience significant growth in revenue due to the increasing adoption of its Renuvion technology and the expanding GLP-1 drug market, as well as its expanding international presence in countries like China and South Korea. This, coupled with cost controls, puts the company on track for long-term revenue scale and improved profitability, with a projected 4.7x EV/sales multiple and price target of $6 based on their FY26E sales estimate of $54.3M, $33.0M in cash, $34.6M in debt, and 44.1M diluted shares outstanding. However, potential risks to our rating and price target include inconsistent commercial execution, slowdown in procedure volumes, competition, pricing pressure, negative clinical trial updates, regulatory delays, margin pressure, supply chain challenges, geopolitical instability, tariffs, and negative financing developments.

Apyx Medical is experiencing a slowdown in procedure volumes, faces competition and pricing pressure, and may experience negative clinical trial updates. While their new product launch, the Ayon all-in-one body contouring system, and the potential for accelerating growth are positive factors, there is also a risk of inconsistent commercial execution hindering sales growth. The company has a strong financial position with a $7M net proceeds from a registered direct offering and amendments to its credit agreement, as well as cost reduction initiatives in place.